Massachusetts Institute of Technology

Memorial Sloan Kettering Cancer Center

Fred Hutchinson Cancer Center

Alice Tzeng

Karl Dane Wittrup

Nai-Kong V Cheung

Steven M Larson

Hong Xu

Sarah M Cheal

Oliver Press

Damian J Green

Yukang Lin

The present disclosure provides compositions and methods for improved pre-targeted radioimmunotherapeutics (PRIT) to treat various hematological disorders, such as B cell hyperproliferative disorders and solid tumors. The disclosed compositions include bispecific antibody compositions having a first domain that specifically bind to an antigen such as CD38, BCMA, Muc1, GPRC5D, or Slam7, and a second domain that specifically binds to a radioactive ligand. Methods include administering the disclosed bispecific antibody reagent and separately administering the radioactive ligand. In some embodiments, a clearing agent is also administered. In some embodiments, the therapeutic methods comprise administering a combination of two or more bispecific antibody reagents. In some embodiments, an enhancing agent, such as ATRA, gamma secretase inhibitor, or dextramethasone, is also administered to enhance expression of the target antigen on the target cells.

Bispecific antibodies specific for treating hematological malignancies

Described herein are multi-specific binding agents that bind A33 and 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid. Also provided herein are methods of using multi-specific binding agents or compositions thereof for the detection, prevention, and/or therapeutic treatment of diseases characterized by expression of the A33 glycoprotein antigen, in particular, colorectal cancer.

Multi-specific antibodies with affinity for human A33 antigen and DOTA metal complex and uses thereof

Growing community of inventors

Beachwood, OH, United States of America

Alice Tzeng